Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.

¹ Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
² F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
³ Moores Cancer Center, University of California San Diego, San Diego, CA.
⁴ Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
⁵ Malaghan Institute of Medical Research, Wellington, New Zealand.
⁶ Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
⁷ Queen Elizabeth II Health Science Center, Halifax, NS, Canada.
⁸ Department of Internal Medicine III, University Hospital Ludwig-Maximilians University Munich, Munich, Germany.
⁹ Monash Hematology, Monash University, Clayton, VIC, Australia.
¹⁰ Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada.
¹¹ Hospital Ramon y Cajal, Madrid, Spain.
¹² AbbVie, Inc., North Chicago, IL.
¹³ Department of Internal Medicine III, Ulm University, Ulm, Germany.
¹⁴ Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
¹⁵ Department of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
¹⁶ Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
¹⁷ Genentech, South San Francisco, CA.

No abstract available

Publication types